Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 8

Managing Suboptimal Adherence to HIV Medications

Published on: 
, , ,

The panel discusses strategies to predict patients who will have poor adherence to their HIV medications and how to select the best treatment options for them.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

  1. When selecting treatment, how do you approach the topic of drug resistance with your patients?
    1. How do discussions vary based on regimen?
    2. When do you have these discussions? Why?
    3. How do patients respond when you share why you recommend a regimen that will protect them against developing resistance?
  2. How are we doing on predicting which patients will be sub optimally adherent to their HIV medications?
    1. What are patient risk factors? (prior history of taking chronic/daily medication, social determinants of health)
    2. Strategies for identifying individuals at highest risk for poor adherence.